An observational study in Pulmonary Hypertension Due to Lung Diseases and Hypoxia, sponsored by University of Giessen. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-01.
Sponsored by University of Giessen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Hypoxia with a site in Germany — 4 open to participants now, 4 under way, 1 of them phase 3. Hypoxia · Germany.
Among the 35 studies in Hypoxia with a site in Germany, this one is one of 2 that started in 2020, is one of 5 observational ones, and was the 30th registered.
1,081 studies on the registry are indexed under Hypoxia; 213 are open to participants now.
Browse Hypoxia studies →4 of the 35 studies in Hypoxia with a site in Germany are open now. Recruiting first, the newest first:
Schön Klinik Berchtesgadener Land · Sites in Germany
Ages 18–80
Australian and New Zealand Intensive Care Research Centre · Sites in Germany, Australia
Ages 18–65
Technical University of Munich · Sites in Germany
Ages 18–70
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 124 Hypoxia studies recruiting now, 52 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 6
First in 2003; this study’s year is marked. 2 started in 2020.
This study's planned enrollment of 500 is above the median of 79 across 279 observational studies indexed under Hypoxia.
Median enrollment 35 across the 30 interventional studies, 140 across the 4 observational. Of the 27 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 35 has an industry lead sponsor. The 10 most frequent:
University of Giessen is the lead sponsor of 95 studies on the registry; 22 are open to participants now.
University of Giessen has 1 study filed under Hypoxia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 35 studies in Hypoxia with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to investigate the frequency and implications of pulmonary hypertension in lung cancer patients. To do so, data will be collected from all lung cancer patients at the university hospital Giessen. All data will be analyzed for possible hints of pulmonary hypertension as a comorbidity in lung cancer patients. All information will be generated from the regular guidelines based course of treatment and there will be no interventions. This study will serve as a prospective register for all lung cancer patients treated at the university hospital Giessen.
Equivalent to the average of patients with lung cancer in Germany.
Exclusion Criteria:
-
There will not be an intervention.
Other: All lung cancer patients.
There will be no specific interventions. All patients will receive guidelines based therapy of lung cancer and their comorbidities.
Pulmonary function test measured via Spirometry.
vital capacity, total lung capacity, forced expiratory volume in one second, functional vital capacity, diffusing capacity for carbon monoxide, arterial partial pressure of oxygen; all measured as % of predicted normal values.
Time frame: 2 years
sPAP values measured via Echocardiography.
systolic pulmonary artery pressure (sPAP) measured in millimetre of mercury (mmHg).
Time frame: 2 years
Body mass index.
weight and height will be combined to report BMI in kg/m\^2.
Time frame: 2 years
Overall Survival and Progression Free Survival measured in days.
Overall Survival and Progression free survival in days will be determined by Kaplan-Meier Analysis .Measuared in (st) (time from diagnosis to death)
Time frame: 2 years
Measurements of the pulmonary artery diameter (PA) and ascending aorta (AA) diameter measured via computed tomography scan. PA and AA will be measured in millimeters.
PA and AA will be combined to report the PA/AA quotient as indicator for pulmonary hypertension in all lung cancer patients. With a cut off value of ≥ 1 defining pulmonary hypertension.
Time frame: 2 years
6 Minute Walk Test in meters.
The 6 minute walk test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance in meters covered over a time of 6 minutes is used as the outcome.
Time frame: 2 years
Modified Medical Research Council Scale (mMRC).
Scores on the mMRC reach from 0-4, with higher scores indicating greater dyspnea.
Time frame: 2 years
chronic obstructive pulmonary disease assessment test (CAT).
Scores on the CAT reach from 0-40, with higher scores indicating greater dyspnea.
Time frame: 2 years
Plan to share: Undecided
Started Jun 2020 (actual). Primary completion is estimated for Jan 2026, 67 months after the start.
Of 125 non-industry observational studies under Hypoxia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 74. This study's planned 67 months is above that.
Counting every sponsor, half of 155 studies reached it within 14 months; a quarter within 3 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Giessen